Cargando…

Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment

It is estimated that in the United States in 2018 there will be 22,240 new cases of ovarian cancer and 14,070 deaths due to this malignancy. The most common subgroup of this disease is high-grade serous ovarian cancer (HGSOC), which is known for its aggressiveness, high recurrence rate, metastasis t...

Descripción completa

Detalles Bibliográficos
Autores principales: Drakes, Maureen L., Stiff, Patrick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162424/
https://www.ncbi.nlm.nih.gov/pubmed/30200478
http://dx.doi.org/10.3390/cancers10090302
_version_ 1783359143153762304
author Drakes, Maureen L.
Stiff, Patrick J.
author_facet Drakes, Maureen L.
Stiff, Patrick J.
author_sort Drakes, Maureen L.
collection PubMed
description It is estimated that in the United States in 2018 there will be 22,240 new cases of ovarian cancer and 14,070 deaths due to this malignancy. The most common subgroup of this disease is high-grade serous ovarian cancer (HGSOC), which is known for its aggressiveness, high recurrence rate, metastasis to other sites, and the development of resistance to conventional therapy. It is important to understand the ovarian cancer tumor microenvironment (TME) from the viewpoint of the function of pre-existing immune cells, as immunocompetent cells are crucial to mounting robust antitumor responses to prevent visible tumor lesions, disease progression, or recurrence. Networks consisting of innate and adaptive immune cells, metabolic pathways, intracellular signaling molecules, and a vast array of soluble factors, shape the pathogenic nature of the TME and are useful prognostic indicators of responses to conventional therapy and immunotherapy, and subsequent survival rates. This review highlights key immune cells and soluble molecules in the TME of ovarian cancer, which are important in the development of effective antitumor immunity, as well as those that impair effector T cell activity. A more insightful knowledge of the HGSOC TME will reveal potential immune biomarkers to aid in the early detection of this disease, as well as biomarkers that may be targeted to advance the design of novel therapies that induce potent antitumor immunity and survival benefit.
format Online
Article
Text
id pubmed-6162424
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61624242018-10-02 Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment Drakes, Maureen L. Stiff, Patrick J. Cancers (Basel) Review It is estimated that in the United States in 2018 there will be 22,240 new cases of ovarian cancer and 14,070 deaths due to this malignancy. The most common subgroup of this disease is high-grade serous ovarian cancer (HGSOC), which is known for its aggressiveness, high recurrence rate, metastasis to other sites, and the development of resistance to conventional therapy. It is important to understand the ovarian cancer tumor microenvironment (TME) from the viewpoint of the function of pre-existing immune cells, as immunocompetent cells are crucial to mounting robust antitumor responses to prevent visible tumor lesions, disease progression, or recurrence. Networks consisting of innate and adaptive immune cells, metabolic pathways, intracellular signaling molecules, and a vast array of soluble factors, shape the pathogenic nature of the TME and are useful prognostic indicators of responses to conventional therapy and immunotherapy, and subsequent survival rates. This review highlights key immune cells and soluble molecules in the TME of ovarian cancer, which are important in the development of effective antitumor immunity, as well as those that impair effector T cell activity. A more insightful knowledge of the HGSOC TME will reveal potential immune biomarkers to aid in the early detection of this disease, as well as biomarkers that may be targeted to advance the design of novel therapies that induce potent antitumor immunity and survival benefit. MDPI 2018-09-01 /pmc/articles/PMC6162424/ /pubmed/30200478 http://dx.doi.org/10.3390/cancers10090302 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Drakes, Maureen L.
Stiff, Patrick J.
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
title Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
title_full Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
title_fullStr Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
title_full_unstemmed Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
title_short Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
title_sort regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162424/
https://www.ncbi.nlm.nih.gov/pubmed/30200478
http://dx.doi.org/10.3390/cancers10090302
work_keys_str_mv AT drakesmaureenl regulationofovariancancerprognosisbyimmunecellsinthetumormicroenvironment
AT stiffpatrickj regulationofovariancancerprognosisbyimmunecellsinthetumormicroenvironment